Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO)

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics company focused on developing a cost-effective biomarker test to help detect early-stage lung cancer, has announced that it has been selected by the Moffitt Cancer Center, the number

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics company focused on developing a cost effective biomarker test to help detect early-stage lung cancer, has announced a strategic agreement with BBI Solutions, the world’s largest independent producer of

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced the publication of the Company’s Annual Report and Financial Statements for the year ended 31 December 2023: Cizzle Biotechnoloy is developing a blood test

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed a non-binding Memorandum of Understanding for a strategic and exclusive licensing agreement to develop and offer its proprietary test for the CIZ1B

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat

Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced an expansion of its current research programme with the University of York to develop its CIZ1B biomarker technology for early stage cancer diagnosis, and other potential

Cizzle Biotechnology (LON:CIZ), the UK-based diagnostics developer, has announced that it has conditionally raised gross proceeds of £350,000 (before expenses of £17,500) by way of the issue of 16,666,667 new Ordinary Shares at 2.1p per share with

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, has announced its audited results for the year ended 31 December 2022. Chair’s Statement The Group has continued throughout 2022 in developing a blood test for the

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that following successful results from its current research programme with the University of York, due to end this year, that it has today signed a new research

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat

Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, notes the announcement by Conduit Pharmaceuticals Limited that they intend to become a publicly traded company on NASDAQ in the USA via a merger with Murphy Cannon Acquisition

Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced its interim results for the six months ended 30 June 2022. Highlights ·    On 14 February 2022 the Group announced a royalty acquisition agreement with Conduit